Largest longevity-focused companies by market capitalization

Longevity-focused companies constitute an emerging sector developing interventions targeting biological aging processes to extend human healthspan and lifespan. These organizations trade across global exchanges, pioneering approaches from cellular rejuvenation to age-related disease prevention based on fundamental aging biology research.

The longevity sector represents a convergence of innovative biotechnologies. Key scientific characteristics include:

• Senotherapeutic approaches: Therapies selectively eliminating senescent cells accumulating with age.
• Epigenetic reprogramming: Technologies resetting cellular age biomarkers.
• Metabolic pathway modulation: Precision targeting of nutrient-sensing mechanisms.

Sector leader BioAge Labs demonstrated significant clinical validation with its muscle-targeted apelin receptor agonist demonstrating 25% improvement in physical performance metrics in elderly patients after just 4 months. Senolytic innovator Unity Biotechnology develops UBX1325 targeting Bcl-xL pathway, showing >50% reduction in senescent cell burden without affecting healthy cells in Phase 2 trials.

Reprogramming pioneer Altos Labs (private) advances partial epigenetic reset technology demonstrating cellular age reversal in non-human primates. Metabolic approach leader Life Biosciences creates novel TOTIM proteins shown to restore NAD+ levels and mitochondrial function in aged models. Diagnostic capability grows through recent FDA breakthrough designation for TruDiagnostic’s epigenetic clock algorithm showcasing 99% correlation with biological age markers.

Therapeutic synergy strategies emerge: Calico Life Sciences combines ABT-263 senolytics with mTOR inhibitors demonstrating synergistic lifespan extension exceeding 30% in mammalian models. Nutrition-technology integration appears through Elysium Health’s development of combination products maintaining active sirtuin levels in clinical testing.

Large pharmaceutical participation expands: Alkahest initiates Phase 2 trials with GRF6019 plasma fraction showing cognitive improvement in Alzheimer’s patients. Regulatory frameworks are developing: Rebion establishes clinical endpoints for IAG evaluation as primary endpoints for healthspan clinical trials. Cell therapy applications advance with Elevian’s GDF11 program demonstrating multi-tissue regenerative effects after single-dose administration in aging primates. This field offers investment exposure to both therapeutic development and biomarker validation platforms with significant expansion potential.

Regulated broker Invest now: Buy Stocks & ETFs in just 15 minutes from $50 Your capital is at risk. Free demo account & education

The following table contains a list of the leading publicly traded longevity-focused companies by market capitalization across global exchanges. These organizations develop interventions targeting fundamental aging processes with clinical-stage candidates and diagnostic technologies.